跳至主要内容
临床试验/NCT03872518
NCT03872518已完成不适用

A Prospective Case Series Analysis of Initial Users of the Urovac Device

Cedars-Sinai Medical Center1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年4月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
Patient perception of urine spills after using Urovac

研究概览

简要总结

To document usage of the Urovac device among 30 initial users of the device in an acute rehabilitation facility, with analysis of whether and how patients benefitted, challenges encountered, and how benefits and challenges varied by patient type.

详细描述

The Urovac device holds the promise of improving care for many of these patients in a manner that may also significantly decrease costs. The aim of the study is to determine if this device may increase quality of life for patients by reducing urine spills, reducing falls by avoiding urgent situations where patients try to ambulate to the bathroom to avoid wetting sheets, reducing skin breakdown by avoiding urine spills, reducing excoriation of the glans penis, and reducing urinary tract infections.

The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills. Allowing for the evacuation of urine from the urinal significantly improves its functionality. The Urovac can be left in place without risk of overflow or other spillage, such that a patient with UI requires less assistance. Improving the handheld urinal in this manner should thus allow for reduced usage of diapers, catheterization, and institutionalization. For patients with UI requiring hospitalization or institutionalization for other reasons, the Urovac could potentially reduce the associated labor and complication costs. Despite the clear clinical promise of the Urovac, it has only been used by a small number of patients to date. This study will document usage of the Urovac among 30 of the initial users of the device to better understand the benefits and challenges.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male patients who identify as having difficulty with functional urinary incontinence, such that it may be difficult to get to the toilet in time to urinate
  • Patients age 18 or older

排除标准

  • Patients with leg wounds or dysfunction which could be worsened by Urovac device placement
  • Patients under age 18

结局指标

主要结局

Patient perception of urine spills after using Urovac

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Patient perception of urine spills after using Urovac after two-hour use of the device, as measured by the statement: "Urovac helped to avoid urine spills ." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Patient perception of reduced risk of falls

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Patient perception of reduced risk of falls after using Urovac after use of the device, as measured by the statement: "Urovac helped reduce risk of falls related to getting to a toilet." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Patient satisfaction with Urovac device: 5-point scale

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Patient satisfaction with the Urovac device after two-hour use of the device, as measured by the statement: "I would recommend it to someone in a similar situation." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Patient perception of dignity preservation after using Urovac

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Patient perception of dignity preservation after using Urovac after two-hour use of the device, as measured by the statement: "Urovac helped preserve dignity." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Clinician perception of Urovac effectiveness in avoiding foley catheterization or condom catheter

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Clinician perception of Urovac effectiveness in avoiding foley catheterization or condom catheter, as measured by the statement: "Urovac helped patient to avoid foley catheterization or condom catheter." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Patient perception of ulcer prevention

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Patient perception of ulcer prevention after using Urovac after use of the device, as measured by the statement: "Urovac helped avoid decubitus ulcers, or helped keep them dry." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Patient perception of caregiver time spent on helping patient use bathroom

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Patient perception of caregiver time spent on helping patient use bathroom after using Urovac after use of the device, as measured by the statement: "Urovac helped save patient/caregiver time." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Clinician perception of Urovac effectiveness of decreasing development or severity of decubitus ulcers.

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Clinician perception of Urovac effectiveness of decreasing development or severity of decubitus ulcers, as measured by the statement: "Urovac helped patient with decubitus ulcers." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Clinician satisfaction with Urovac device: 5-point scale

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Clinician satisfaction with Urovac device, as measured by the statement: "I would recommend it to a physician colleague." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Clinician perception of Urovac effectiveness of decreasing risk of falls when going to the toilet

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Clinician perception of Urovac effectiveness of risk of falls when going to the toilet, as measured by the statement: "Urovac helped reduce risk of falls related to getting to a toilet." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Clinician perception of Urovac effectiveness of decreasing risk of hospitalization or skilled nursing facility

时间窗: 24 hours after patient is given instructions on how to use Urovac device.

Clinician perception of Urovac effectiveness of decreasing risk of hospitalization or skilled nursing facility, as measured by the statement: "Urovac helped patient avoid hospitalization or skilled nursing facility admission." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

次要结局

  • Average hours of daily use of Urovac by patient(24 hours after patient is given instructions on how to use Urovac device.)
  • Development of urinary tract infection after using Urovac(24 hours after patient is given instructions on how to use Urovac device.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Josh Pevnick

Assistant Professor of Medicine and Associate Director, Division of Informatics

Cedars-Sinai Medical Center

研究点 (1)

Loading locations...

相似试验

A Prospective Case Series Analysis of Initial Users... | 临床试验